Skip to main content
Clinical Trials/ACTRN12615000106538
ACTRN12615000106538
Not yet recruiting
未知

Efficacy and safety of artemisinin-based combination therapy: artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL) in the treatment of uncomplicated falciparum malaria in 4 provinces of Burundi

Ministry of Public Health0 sites528 target enrollmentFebruary 5, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
ncomplicated falciparum malaria
Sponsor
Ministry of Public Health
Enrollment
528
Status
Not yet recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
February 5, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • children aged 6 months to 10 years
  • monoinfection with P falciparum confirmed by microscopy
  • parasitemia between 1000\-200000 parasites (asexual) per microliter
  • fever (equal or greater than 37\.5 celsius) or history of fever within past 24 hours
  • able to swallow oral medication
  • ability and willingness to follow protocol procedures and schedule of assessments
  • written informed consent from parent or guardian

Exclusion Criteria

  • presence of danger and signs of severe malaria
  • mixed infection or infection of than P. falciparum detected by microscopy
  • severely malnourished
  • fever due to other diseases (measles, acute lower respiratory tract infection, severa diarrhea); chronic or severe hepatic, renal or cardiac diseases; HIV/AIDS
  • clinical signs of acute jaundice
  • abnormal level of granulocytes or liver transaminases
  • regular medication that could interfere with antimalarial pharmacokinetics;
  • history of hypersensitivity reactions or contraindications to any medicines being used

Outcomes

Primary Outcomes

Not specified

Similar Trials